Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia

Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL). However, such resistance-conferring mutations are rare and do not explain most disease recurrence seen in the clinic. We have generated stable ATO-resistant promyelocyti...

Descripción completa

Detalles Bibliográficos
Autores principales: Balasundaram, Nithya, Ganesan, Saravanan, Chendamarai, Ezhilarasi, Palani, Hamenth Kumar, Venkatraman, Arvind, Alex, Ansu Abu, David, Sachin, Kumar, Swathy Palani, Radhakrishnan, Nair Reeshma, Yasar, Mohammed, Krishna, Sanjeev, Korula, Anu, Kulkarni, Uday, Janet, Nancy Beryl, Balasubramanian, Poonkuzhali, Mathews, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791572/
https://www.ncbi.nlm.nih.gov/pubmed/34625794
http://dx.doi.org/10.1182/bloodadvances.2021005300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791572/
https://www.ncbi.nlm.nih.gov/pubmed/34625794
http://dx.doi.org/10.1182/bloodadvances.2021005300

Ejemplares similares